ENVB

3.90

9.30% -0.40

Handel nachbörslich: 3.98 0.08 +2.05%

Enveric Biosciences Inc (ENVB)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$4.30

Offen:

$4.28

24-Stunden-Volumen:

1.44M

Relative Volume:

26.36

Marktkapitalisierung:

$2.70M

Einnahmen:

Nettoeinkommen (Verlust:

$-15.08M

KGV:

-0.6075

EPS:

-6.42

Netto-Cashflow:

$-11.56M

1W Leistung:

-21.92%

1M Leistung:

-20.34%

6M Leistung:

-55.28%

1J Leistung:

-67.50%

1-Tages-Spanne:

$3.90

$4.83

1-Wochen-Bereich:

$3.8805

$5.0985

52-Wochen-Spanne:

$3.8805

$43.80

Enveric Biosciences Inc Stock (ENVB) Company Profile

Firmenname

Enveric Biosciences Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (678)

Telefon

239-302-1707

Adresse

4851 TAMIAMI TRAIL N, SUITE 200, NAPLES

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

ENVB's Discussions on Twitter

Vergleichen Sie ENVB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENVB Enveric Biosciences Inc	3.90	2.70M	0	-15.08M	-11.56M	-6.42
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

Enveric Biosciences Inc Aktie (ENVB) Neueste Nachrichten

08:25 AM

Biotech Funding Alert: Enveric Secures $5M to Advance Neural Therapeutics Pipeline - StockTitan

08:25 AM

08:14 AM

Enveric Biosciences Announces Pricing of $5 Million Public Offering - Business Wire

08:14 AM

06:51 AM

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office - BioSpace

06:51 AM

04:57 AM

Enveric Passes Key Milestone on Patent Path for Mental-Health Treatment - MarketWatch

04:57 AM

Jan 29, 2025

Enveric Biosciences stock hits 52-week low at $0.29 By Investing.com - Investing.com South Africa

Jan 29, 2025

Jan 28, 2025

Enveric Biosciences stock hits 52-week low at $0.29 - MSN

Jan 28, 2025

Jan 26, 2025

Jay Pharma Inc. Announces Appointment of Sara Dakar as Vice President, Product Development - Marketscreener.com

Jan 26, 2025

AMERI Holdings, Inc. Announces Executive Changes -April 08, 2019 at 08:00 am EDT - Marketscreener.com

Jan 26, 2025

AMERI Holdings, Inc. Announces Board Changes -December 12, 2018 at 06:59 am EST - Marketscreener.com

Jan 26, 2025

R. James Woolsey Joins AMERI Holdings as Strategy Consultant -January 27, 2020 at 08:00 am EST - Marketscreener.com

Jan 26, 2025

Ameri Holdings, Inc. Approves Director Changes -August 17, 2018 at 08:00 am EDT - Marketscreener.com

Jan 26, 2025

Ameri Holdings, Inc. Announces Board Changes -April 02, 2019 at 04:01 pm EDT - Marketscreener.com

Jan 26, 2025

Robert Wilkins Joins Jay Pharma as Chief Medical Officer -July 29, 2020 at 09:00 am EDT - Marketscreener.com

Jan 26, 2025

Enveric Biosciences Appoints Arash Asher to Scientific Advisory Board -May 12, 2021 at 07:30 am EDT - Marketscreener.com

Jan 26, 2025

Jan 25, 2025

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Marketscreener.com

Jan 25, 2025

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally - Marketscreener.com

Jan 25, 2025

Jan 22, 2025

Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN

Jan 22, 2025

Jan 21, 2025

Enveric Biosciences Announces 1-for-15 Reverse Stock Split By Investing.com - Investing.com UK

Jan 21, 2025

Jan 12, 2025

Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World

Jan 12, 2025

Jan 07, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025” - BioSpace

Jan 07, 2025

Jan 06, 2025

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8 - Business Wire

Jan 06, 2025

Enveric Biosciences CEO to Present Future of Psychedelics Vision at Major JP Morgan Week Events - StockTitan

Jan 06, 2025

Jan 04, 2025

Enveric Biosciences to Release Investor Presentation - TipRanks

Jan 04, 2025

Dec 24, 2024

ENVB Stock Touches 52-Week Low at $0.3 Amid Market Challenges - Investing.com Nigeria

Dec 24, 2024

Enveric Biosciences (NASDAQ:ENVB) Shares Down 4.6% – Here’s Why - Defense World

Dec 24, 2024

Dec 03, 2024

Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives - Microdose Psychedelic Insights

Dec 03, 2024

Enveric Biosciences secures patents for neuroplasticity drugs By Investing.com - Investing.com Canada

Dec 03, 2024

Dec 02, 2024

Enveric Biosciences Expands Patent Portfolio for Novel Psilocybin Compounds - StockTitan

Dec 02, 2024

Nov 27, 2024

Enveric advances neuroplastogen EB-003 through PK studies - BioWorld Online

Nov 27, 2024

Nov 25, 2024

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results - Benzinga

Nov 25, 2024

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Business Wire

Nov 25, 2024

Enveric Biosciences faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria

Nov 25, 2024

Enveric Biosciences faces potential Nasdaq delisting - Investing.com India

Nov 25, 2024

Nov 18, 2024

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders - Benzinga

Nov 18, 2024

Nov 16, 2024

atai Life Sciences and Enveric Biosciences Report Q3 2024 Results - Microdose Psychedelic Insights

Nov 16, 2024

Nov 15, 2024

Enveric Biosciences narrows net loss, advances lead drug candidate - Green Market Report

Nov 15, 2024